Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: ssspta1202txn

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

```
Web Page URLs for STN Seminar Schedule - N. America
                "Ask CAS" for self-help around the clock
NEWS
NEWS
     3 SEP 09 ACD predicted properties enhanced in REGISTRY/ZREGISTRY
NEWS 4 OCT 03 MATHDI removed from STN
NEWS 5
        OCT 04 CA/CAplus-Canadian Intellectual Property Office (CIPO) added
                to core patent offices
        OCT 13
                New CAS Information Use Policies Effective October 17, 2005
NEWS 6
NEWS 7
       OCT 17
                STN(R) AnaVist(TM), Version 1.01, allows the export/download
                of CAplus documents for use in third-party analysis and
                visualization tools
NEWS 8
        OCT 27
                Free KWIC format extended in full-text databases
        OCT 27 DIOGENES content streamlined
NEWS 9
NEWS 10 OCT 27 EPFULL enhanced with additional content
                CA/CAplus - Expanded coverage of German academic research
NEWS 11
        NOV 14
NEWS 12
        NOV 30
                REGISTRY/ZREGISTRY on STN(R) enhanced with experimental
                spectral property data
```

NEWS EXPRESS NOVEMBER 18 CURRENT VERSION FOR WINDOWS IS V8.01,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005.
V8.0 USERS CAN OBTAIN THE UPGRADE TO V8.01 AT
http://download.cas.org/express/v8.0-Discover/

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 17:23:51 ON 30 NOV 2005

=> file reg
COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION

FILE 'REGISTRY' ENTERED AT 17:24:35 ON 30 NOV 2005 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 29 NOV 2005 HIGHEST RN 868943-57-1 DICTIONARY FILE UPDATES: 29 NOV 2005 HIGHEST RN 868943-57-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

Uploading C:\Program Files\Stnexp\Queries\10775699.str

chain nodes :
7 13
ring nodes :
1 2 3 4 5 6 8 9 10 11 12
ring/chain nodes :

10/ 775,699

14 chain bonds: 4-7 6-13 7-8

ring/chain bonds :

2-14

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-12 9-10 10-11 11-12

exact/norm bonds :

2-14 4-7 6-13 7-8 8-9 8-12 9-10 10-11 11-12

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

G1:C,O,S,N

Match level:

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom 13:CLASS 14:CLASS

L1 STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS

L1 STR

G1 C, O, S, N

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sample

SAMPLE SEARCH INITIATED 17:25:04 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 60 TO ITERATE

100.0% PROCESSED 60 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 736 TO 1664

PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s 11 full

FULL SEARCH INITIATED 17:25:10 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1438 TO ITERATE

100.0% PROCESSED 1438 ITERATIONS

SEARCH TIME: 00.00.01

23 ANSWERS

161.54

L3

23 SEA SSS FUL L1

=> file hcaplus

COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION

161.33

FULL ESTIMATED COST

FILE 'HCAPLUS' ENTERED AT 17:25:17 ON 30 NOV 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 30 Nov 2005 VOL 143 ISS 23 FILE LAST UPDATED: 29 Nov 2005 (20051129/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 17:23:51 ON 30 NOV 2005)

FILE 'REGISTRY' ENTERED AT 17:24:35 ON 30 NOV 2005

L1 STRUCTURE UPLOADED

L2 0 S L1 SAMPLE L3 23 S L1 FULL

FILE 'HCAPLUS' ENTERED AT 17:25:17 ON 30 NOV 2005

=> s 13

L4 9 L3

=> d 14 1- ibib abs hitstr
YOU HAVE REQUESTED DATA FROM 9 ANSWERS - CONTINUE? Y/(N):y

10/ 775,699

L4 ANSVER 1 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER:
2005:387769 BCAPLUS

163:357022

Fittle:
Ethyl 5-saxino-3-(4,6-dimethylpyrimidin-2-ylamino)-1-genitropherylsulforpyl)-HE-pyrazole-4-carbomylate and ethyl
5-saxino-3-(4,6-dimethylpyrimidin-2-ylamino)-1-(2-nitropherylsulforpyl)-HE-pyrazole-4-carbomylate

AUTHOR(5):
W. Chao; Zhu, You Quan; Li, Eus Bin; Li, Jian Rong;
Ren, Xue Ling; Li, Bin; Yang, Hua Zheng

CORPORATE SOUNCE:
State Key Laboratory, Institute of Riemento-Organic
Chemistry, Nankai University, Tianjin, 300071, Peop.
Rep. Chins
Comminications (2005), C61(5), o281-0283

COUNCE:
Comminications (2005), C61(5), o281-0283

COUNCE:
Comminications (2005), C61(5), o281-0283

COUNCE:
DOCUMENT TYPE:
Journal
LANGUAGE:
Balcavell Publishing Ltd.
Journal
LANGUAGE:
Structures of Rt 5-saxino-3-(4,6-dimethylpyrimidin-2-ylamino)-1methyl-HE-pyrazole-4-carbomylate, CliBHON602, (1), and Rt
5-saxino-3-(4,6-dimethylpyrimidin-2-ylamino)-1-(2-nitrophenylsulfonyl)-HEpyrazole-4-carbomylate, CliBHON602, (1), and Rt
Structures of Rt 5-saxino-3-(4,6-dimethylpyrimidin-2-ylamino)-1-(2-nitrophenylsulfonyl)-HEpyrazole-4-carbomylate, CliBHON602, (1), and Rt
Structure of Rt 5-saxino-3-(4,6-dimethylpyrimidin-2-ylamino)-1-(2-nitrophenylsulfonyl)-HEpyrazole-4-carbomylate, CliBHON602, (1), and Rt
Structure of Rt 5-saxino-3-(4,6-dimethylpyrimidin-2-ylamino)-1-(2-nitrophenylsulfonyl)-HEpyrazole-4-carbomylate, CliBHON602, (1), and Rt
Structure of Rt 5-saxino-3-(4,6-dimethylpyrimidin-2-ylamino)-1Resolution of Rt 5-saxino-3-(4,6-dimethylpyrimidin-2-ylamino)-1-(2-nitrophenylsulfonyl)-HERen (Properties), SFN (Synthetic preparation), PREP (Preparation)
(preparation and crystal structure of)
RN 865648-55-49 RCAPIUS
RN 185648-55-49 RCAPIUS

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 865648-59-5 ECAPLUS
R18-Pyrazole-4-carboxylic acid, 5-amino-3-[(4,6-dimethyl-2pyrimidinyl]amino]-1-[(2-nitrophenyl)sulfonyl]-, ethyl ester (9CI)
RNDEX NAME)
(CA

L4 ANSWER 2 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN ACCESSION NUMBER: 2005:354830 HCAPLUS

DOCUMENT NUMBER:

TITLE:

AUTHOR(S):

CORPORATE SOURCE:

PUS COPYRIGHT 2005 ACS on STN 22005;354830 HCAPLUS 143:386986 Synthesis and biological activity of 3-pyrimidylaminopyrazoles Zou, Xiao-Haor Wu, Chaor Zhou, Chuan-Zheng; Ren, Xue-Ling; Yang, Bha-Zheng State Key Laboratory of Elemento-organic Chemistry, Institute of Elemento-Organic Chemistry, Nankai University, Tianjin, 300071, Peop. Rep. China Gaodeng Xuexiao Husava Xuebao (2005), 26(3), 456-460 CODEN: KTHPUM; ISSN: 0251-0790 Gaodeng Jiaoyu Chubanshe Journal Chinese SOURCE:

PUBLI SHER:

DOCUMENT TYPE: LANGUAGE: AB A series

MRINT TYPE: Journal

WAGE: Chinese

A series of novel pyrimidylamino-pyrazole derivs. were synthesized and their biol. activities were studied. All of the products were confirmed by HE NOR and elemental snal., and some of them were characterized by IR and MS. The bioassay results indicated that some of the title compds. have a high fungicidal activity or herbicidal activity. In addition, the structure-activity relationship was discusses.

885848-58-49 88548-58-959 886837-85-89

885847-78-09 886847-13-39 886847-8-69

886547-78-79

RL: AGR (Agricultural use); BSU (Biological study), unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)

IŤ

(synthesis of pyrimidylaminopyrazoles as fungicide and herbicide) 85568-58-4 HCAPLUS
HR-Pyrazole-4-carboxylic acid, 5-amino-3-[(4,6-dimethyl-2-pyrimidinyl)amino]-1-methyl-, ethyl ester (9CI) (CA INDEX NAME)

ONE OR HORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 865648-59-5 ECAPLUS
CN IN-Pyrazole-4-carboxylic acid, 5-amino-3-[(4,6-dimethyl-2pyrimidinyl)amino]-1-[(2-nitrophenyl)sulfonyl]-, ethyl ester (9CI) (CA
INDEX NAME)

ANSWER 1 OF 9 BEAPLUS COPYRIGHT 2005 ACS on STN

ONE OR HORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 2 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE RN 866547-69-5 HCAPLUS

NAME TAUTOMENT DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE 866547-69-5 ENCAPLIS.

1H-Pyrazole-4-carboxylic acid, 1-acetyl-5-amino-3-[(4,6-dimethyl-2-pyrimidinyl)amino)-, ethyl ester (9CI) (CA INDEX NAME)

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

ON MONE INJURIALLE COURSE OF THE STREET OF T

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE RN 866547-71-9 HCAPLUS
CN HE-Pyrazole-1, 4-discarboxylic acid, 5-amino-3-[(4,6-dimethyl-2-pyrimidinyl)amino]-, diethyl ester (9CI) (CA INDEX NAME)

ANSWER 2 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 866547-72-0 BCAPIUS
CN 1H-Pyrazole-4-carboxylic acid, 5-amino-3-[(4,6-dimethyl-2pyrimidinyl)amino]-1-(phenylmethyl)-, ethyl ester (9CI) (CA INDEX NAME)

CME OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 866547-74-2 ECAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 5-amino-3-[(4,6-dimethyl-2pyrimidinyl)mmino]-1-(phenylsulfonyl)-, ethyl ester (9CI) (CA INDEX NAME)

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 866547-75-3 BCAPLUS
CN [H-Pyrazola-4-carboxylic acid, 5-amino-3-[(4,6-dimethyl-2pyrimidimyl)amino]-1-[(4-methylphenyl)sulfonyl]-, ethyl ester (9CI) (CA
INDEX NAME)

L4 ANSWER 3 OF 9
ACCESSION NUMBER:

DOCLINEARY NUMBER:

TITLE:

INVENTOR(5):

PATENT ASSIGNEE(8):

DOCLINEART TUPE:

DOC

Patent English

DOCUMENT TYPE: LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

	PAT	TENT	NO.			KIN	D	DATE			APPL	ICAT	ION	NO.		D	ATE	
							-									-		
	WO	2005	0307	58		A1		2005	0407		WO 2	004-	US31	212		21	0040	922
		V:	AΕ,	AG,	AL,	AM,	AT,	AU,	AZ,	BA,	BB,	BG.	BR.	BW.	BY.	BZ.	CA.	Œ,
			CN,	œ.	CR.	cu.	CZ.	DE,	DK.	DM.	DZ.	EC.	KE.	EG.	ES.	FI.	GB.	GD.
								ID,										
								LV,										
								PL.										
								TZ,										
		DW.	BW,															
								RU,										
								GR,										
						DF,	ы,	CF,	u,	CI,	ca,	un,	GN,	GQ,	GW,	nu,	nn,	NE,
				TD,														
	V5	2005	0854	97		A1		2005	0421	- 1	US 21	004-:	9460	55		20	00409	3 21
PRIO	UTY	' APP	LN.	INPO	. :					1	US 21	003-	5058	93P	1	2 20	00309	925
OTHE	R SC	URCE	(5):			MAR	PAT	142:	3738	59								•

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [X = N, CR5; R1-2 = H, alkyl, alkonyalkyl, etc.; R3 = (heterolaryl, cycloalkyl, etc.; R4 = H, (cycloalkyl, etc.; R5 = H, alkyl; Z = hydroxyalkyl, etc.] are prepared For instance, II is prepared in 5 steps from a substituted pyrimidine, 2-methyl-2H-[1,2,4]triazol-3-ylamine, and a prior art homochiral dihydroxy acetonide derivative I are BKG-CoA reductase inhibitors and are active in inhibiting holesterol biosynthesis, modulating blood serum lipids, for example, lowering LDL cholesterol and/or increasing BDL cholesterol, and reating hypercholesterolemia, hypertriglyceridenia and theroxoleroxis as well as Alzheimer's disease and osteoporoxis [no data].

R8-26-81-87-84696-83-87-849470-16-29

R81-762 (Pharmacological activity), SPN (Synthetic preparetric).

849470-20-09
RL: PAC (Pharnacological activity), SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Uses)
(Uses)
(preparation of pyrimidine and pyridine derivs. useful as EMG-CoA reductase
inhibitors)
RN 849469-81-4 HCAPLUS
CN 6-Heptenoic acid, 7-[4-(4-fluorophemyl)-6-(1-methyl-thyl)-2-[(1-methyl-thyl)-2-[(1-methyl-thyl)-3-], Security (CA)

(Continued) ANSWER 2 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 866547-78-6 HCAPIUS
CN 1H-Pyrazole-4-carbomylic acid, 3-[(4,6-dimethyl-2-pyrimidinyl)amino]-,
ethyl ester (9CI) (CA INDEX NAME)

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866547-79-7 HCAPLUS

CN Pyraciol(1,5-a)pyriaddine-3-carboxylic acid, 2-[(4,6-dimethyl-2pyriaddinyl)amino]-5,7-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

ANSWER 3 OF 9 ECAPLUS COPYRIGHT 2005 ACS on STN INDEX NAME) (Continued)

Absolute stereochemistry. Double bond geometry as shown.

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 849469-83-6 HCAPJUS

28-87-20-6 - ([18]-2-(4-(4-fluorophenyl)-6-(1-methylethyl)-2-[(1-methyl-1H-pyraxol-3-yl)amino]-5-pyrimidinyl]ethenyl]tetrahydro-4-hydroxy-,
(45,65)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry as shown.

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

80 484870-16-2 HCAPLUS

6-Hcaptonic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[(1-methyl-1Hpyrazol-3-yl) (methylaulfonyl) aminol-5-pyrimidinyl)-3,5-dihydromy-,
(3R,55,65)- (9C1) (CA INDEX NAME)

Absolute steraochemistry. Double bond geometry as shown.

ANSWER 3 OF 9 BICAPLUS COPYRIGHT 2005 ACS on STN (Continued)

849470-20-8 HCAPLUS
6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(1-methyl-18-pyrazol-3-yl)amino]-5-pyrimidinyl]-3,5-dihydromy-, (3R,55,6E)-(9C1) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry as shown.

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

RL: FAC (Pharmacological activity): SPN (Synthetic preparation): TEU (Therapeutic use): BIOL (Biological study): PREP (Preparation): USES (Uses)

(Uses)
(Uses)
(protein kinase inhibitor; preparation of (pyrimidinylamino)pyrazoles as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)
438204-95-6 HCAPLUS
2,4-Quinazolinediamine, N,N'-bis(5-ethyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L4 ANSVER 4 OF 9 HCAPLUS COPTRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:140796 HCAPLUS
DOCUMENT NUMBER: 142:240444
TITLE: Preparation of 3-(4-pyrimidinylamino)-H-pyrazoles as protein kinase inhibitors, especially of Aurora-2 and 65x-3
INVENTOR(5): Bebhington, David; Charrier, Jean-damien; Golec, Julians Miller, Andrew; Knegtel, Ronald
UK
SOURCE: US. Pat. Appl. Publ., 164 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1

DOCUMENT TYPE: LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005038023	Al	20050217	US 2003-632428	20030801
PRIORITY APPLN. INFO.:			US 2003-632428	20030801
OTHER SOURCE(5):	MARPAT	142:240444		

The title compds. I [21 - N, CR8; Z2 - N, CH; and at least one of 21 and 22 - N; Rb, Rc - TR3, LZR3; CZRbRc - (un)substituted fused (hetero)cycle; Q - NR4, O, S, etc.; R1 - TD; D - (un)substituted mono- or bicyclic (hetero)aryl, heterocyclyl, carbocyclyl; T - a bond, alkylidene (un)interrupted by O, S, NR4, CO, etc.; Z - alkylidene; L - O, S, SO, SO2,

L4 ANSWER 5 OF 9 BCAPLUS COPYRIGHT 2005 ACS ON STN
ACCESSION NUMBER:
DOCUMENT NUMBER:
137:169539
Freparation of 3-(4-pyrimidinylamino)-IH-pyraroles as protein kinase inhibitors, especially of Aurore-2 and 6SK-3, for treatment of cancer, diabetes, and Alzheimer's disease

INVENTOR(S):
BABBINGTON, David Charrier, Jean-Damien; Golec, Julian M. C., Miller, Andrew Knegtel, Ronald Vertex Pharmaceuticals Incorporated, USA PCT Int. Appl., 335 pp.
CODEN: PIXED2
DOCUMENT TYPE:
LANGUAGE:
FAMILY ACC. NUM. COUNT:
FAMI

DOCUMENT TYPE: LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

PA	TENT	NO.				DATE						NO.		D	ATE	
	2002				A1	2002						^		-	0011	210
•0	2002 V:					AU,										
	• •					DK,										
						IN, MD,										
					YU.	SG,	31,	3K,	26,	10,	ın,	ıĸ,	11,	12,	un,	ω,
	nu.											-				~
	M#:					MZ,										
						FR,										
	2422		ы,	CF,		CH,										
	2432 2432				XX XX	2002										
	2002													2		
wu	2002 W:				,A1	2002 AU,										
	•:															
						DK.										
						IN,										
						MD,										
						SG,	51,	SK,	SL,	TJ,	TM,	TR,	TT,	TZ,	UA,	UG,
					YU,											
	KA:					MZ,										
						FR,										
			ы,			CH,										
	2432				AA	2002	0906		CA Z	001-	24 3Z	223		Z	0011	219
80	2002					2002										
	w:					ΑU,										
						DK,										
						IN,										
						MD,										
						SG,	51,	SK,	SL,	TJ,	TH,	TR,	П,	TZ,	UA,	UG,
					YU,											_
	RW:					MZ,										
						FR,										
				C₹,	Œ,	CH,										
	2003		61		A1	2003		1	JS 21	001-	2697	5		21	0011	219
	6653				ВZ	2003								_		
	2003		43		A1	2003		,	JS 21	001-	2516	4		21	0011	219
	6664			٠	B2	2003						_				
	2003					2003			JS 20						0011	
	2003		75		A1	2003		,	JS 20	301-3	2700	1		20	0011	219
	6653				BZ	2003										
	2003		90			2003			JS 20						0011	
ΚÞ	1345	722			A1	20030	D924	1	RP 20	301-2	2710	61		21	2011	219

L4 ANSWER 5 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN

14	VN2AT	3 5 C															
	R	: AT,	, BE,	Œ,	DZ,	DK,	ES, E	'n,	GB,	GR,	. IT,	LI,	w,	NL,	SE	, MC,	PT,
		IE.	. SI.	LT.	LV,	FI.	RO, M	ĸ.	CY.	AL.	TR						
	EP 13				A1		00309		- 1	EP 2	2001-	9945	10			20011	219
	R			CH.												, MC,	
					LV,								ш,		34	,,	,
	EP 13		, 31,	ы,	Ai		00310					2738				20011	210
				_												20011	
	К	: AT,										Li,	ш,	NL,	SE	, AC,	PT,
			, SI,	LT,	LV,												
	NZ 52				A		00404					5264				20011	
	JP 20	045187	703		T2	20	00406	24				5631				20011	219
	JP 20	045187	743		T2	20	00406	24	•	JP 2	2002-	5659	76			20011	219
	JP 20	045194	179		T2	21	00407	102		JP 2	2002-	5679	28			20011	219
	US 200	042148	114		Al	21	00410	28		us 2	2001 -	2699	2			20011	219
	CN 15				A	26	00410 00411	24				8221				20011	
	NZ 52				Ä							5264				20011	
	NZ 52				Ä	37	00506 00508	26	:			5264				20011	
	US 200				Äl		00301					3468				20011	
	US 663		104		B2		00301		,	J 2	.001-	3408	3			20011	220
													_				
	US 200		182		A1		00301			JS 2	.001-	3401	9			20011	220
	US 67				B2		00404										
	ZA 200				A		00406					4468				20030	
	ZA 200				λ		00406					4469				20030	
	ZA 200				Α	20	00406	24	2	ZA 2	:003-	4470				20030	609
	ZA 201	030044	171		A	20	30406	24	7	ZA 2	2003-	4471				20030	609
	ZA 200	030044	173		A	20	00406	24	2	ZA 2	2003-	4473				20030	609
	ZA 200	030044	175		A	20	00406	24	2	ZA 2	2003-	4475				20030	609
	ZA 200	030044	172		A	20	00406	25	2	ZA 2	003-	4472				20030	609
	ZA 200	030044	174		A		00406					4474				20030	
	NO 200	330027	104		À		00308					2704				20030	
	NO 200				Ä		0308					2736				20030	
	US 200				Äl		00411					6248				20030	
	US 200				λì		0406					6923				20030	
	US 200				λl		0408					7223				20031	
	US 200				A1		0407					7364				20031	
	US 200				A1		0408					7756				20040	
	JP 200				A2	20	0504	14				3669				20041	
PRIOR	ITY A	PLN.	INFO	.:								25781				20001	
												2869				20010	
												23279		P		200001	
												9526				200109	
									U	15 2	001-	95560	D1	A	3	200109	914
									J	TP 2	002-	55793	38	Α	3	20011	219
									υ	IS 2	001-	26966	5	A	1	20011	219
									¥	ro 2	001-	US491	139	v		200112	219
									¥	no 2	001-	US503	312	¥	1 :	20011	219
												US510	031	ÿ		20011	219
												34019			3	200112	220
												34683		Ä	ī :	20011	220
OTHER	SOURC	E(S)			MARPA	AT 13	17:16	953					•	-			

ANSWER 5 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued) are useful for the treatment of diseases assocd. with protein kinases, such as diabetes, cancer, and Alzheimer's disease (no data).
438204-95-6F, (5-Ethyl-1H-pyrazol-3-y1)[2-(5-ethyl-1H-pyrazol-3-y1amino)quinazolin-4-y1]amine
RI: FAC (Pharmacological activity); SFN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(protein kinase inhibitor; preparation of (pyrimidinylamino)pyrazoles as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)
438204-95-6 HCAPUS

2.4-Quinazolinediamine, N,N'-bis(5-ethyl-lH-pyrazol-3-yl)- (9CI) (CA INDEX NAME)

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
REFERENCE COUNT:

3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 5 OF 9 ECAPLUS COPYRIGHT 2005 ACS on STN

L4 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER:
DOCUMENT NUMBER:
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
137:109292
13

FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

P	ATENT	NO.			KIN	D	DATE			APPL	ICAT	ION	NO.		D	ATE	
_						-									-		
	0 2002	0591	11		A2		2002	0801		WO 2	001-	US51	120		2	0011	219
	V:	ΑĒ,	AG,	AL,	AM,	AΤ,	AU,	AZ,	BA,	BB,	BG,	BR,	BY,	BZ,	CA,	Œ,	αı,
							DK.										
		GH.	HR.	HU.	ID.	IL.	IN.	15.	JP.	KE.	KG.	KP.	KR.	KZ.	LC.	LK.	LR.
							HD,										
							SG,										
					YU.							,		,	,		,
	RW:						MZ.	SD.	SI	52.	TZ.	UG.	ZM.	ZW.	AT.	RR.	CH.
							FR.										
							αŧ,										
C	4 2432		,	,	AA	,	2002			CĂ 2				,	2	0011	219
	4 2432				AA		2002	0229		CR 2	001 –	2432	303		2	በለነገ	210
	2002		61				2002	0029		en 2	001_	11640	139			0011	210
-	V:						AU,										
							DX.										
							IN,										
							MD,										
							SG,										
					YU,			31,	эĸ,	3L,	10,	ın,	ın,	11,	14,	ŲΛ,	υς,
	mr.																_
	KW:						MZ,										
							FR,										
~			ы,	u,			CH,										
	A 2432 2002						2002										
					A1		2002										
	w:						AU,										
							DK,										
							IN,										
							MD,										
							SG,	SI,	SK,	SL,	TJ,	TH,	TR,	TΤ,	TZ,	UA,	υG,
					YU,												
	RV:						MZ,										
							FR,										
				CF,	œ,		CH,										
	2003		51		A1 B2		2003		1	US 20	001-	2697	5		20	0011	219
US	6653	300			B2		2003										
US	2003	0365	13		AΊ		2003(,	US 20	001-	2516	4		20	0011	219
US	2003 6664 2003	247			B2		2003:										
US	2003	0550	68		A1		20036			US 20					20	0011	219
US	2003	3782	75		A1		20030			US 20	001-	2700	1		20	0011	219
US	6653	301			B2		2003										
บร	20036 20036 6653 2003	10509	90		A1		20030	0605	ι	US 20	001-	2696	5		20	011	219

	SWEER 6		9 1	BCAP:	LUS													
EP	13459	22			A1		2003	0924		EP	200	1-2	2710	61			20011	219
	R:	AΤ,	BE,	CĦ,	DE,	DX,	ES,	FR,	GB	, G	R. I	T.	LI,	w,	NL,	SB	, MC,	PT,
		IE,	SI,	LT,	LV,	FI,	RO,	MK,	CY	. A	L, T	'n						
22	13459				A2		2003	0924		EP	200	1-9	9933	50			20011	219
	R:	AT,	BE,	Œ,	DE,	DX,	ES,	FR,	GB.	. G	R. I	Ť.	ш.	w.	NL.	SE	, MC,	PT.
		IR.	SI.	LT.	LV.	PI.	RO.	MX.	CY	. ж	T	R						
BR	20010 13559	1649	3		A		2003	0930		BR	200	1-1	649	3			20011	219
EP	13559	05			A1		2003	1029		EP	200	1-2	738	51			20011 20011	219
	R:	AT,	BE,	CH,	DE,	DX.	ES,	FR,	GB.	, G	R. I'	T.	LI.	w.	NL,	SE	, MC.	PT.
		IE,	51,	LT,	LV,	PI,	RO,	MX.	CY	. A	L. T	R						
NZ	52646	8			A		2004	0326		NZ	200	1-5	264	58			20011	219
NZ	52647	2			A	- 3	2004	0430		NZ	200	1-5	264	12			20011	219
JP	20045	1792	6		T2	:	2004	0617		JP	200	2-5	594	13			20011	219
JP	20045	1874	3		T2 T2 A1 A	- :	2004	0624		JP	200	2-5	659	16			20011	219
JP	20045	1947	9		72	- :	2004	0702		JP	200	2-5	6792	28			20011	219
US	20042	1481	4		A1	- 1	2004	1028		US	200	1-2	699	2			20011	219
CN	15498	12			A		2004	1124		CN	200	1-8	2210)5			20011	219
NZ	52647	3				- 1	2005	0624		NZ	200	1-5	264	73			20011	219
US	20030	0416	4		Al	:	2003	0102		US	200	1-3	4683	1			20011	220
US	66569	39			B2	:	2003	1202									20011 20011 20011 20011 20011 20011 20011 20011	
US	20030	2288	5		Al	:	2003	0130		US	200	1-3	4019	•			20011	220
US	67272	51			B2			0427										
ZA	20030	0446	8		Α	:	2004	0624		ZA	200	3-4	468				20030	609
2A	20030	0446	9		Α	:	20040	0624		ZΑ	200	3-4	468				20030	609
ZA	20030	0447	0		λ	- 2	20041	0624		ZΑ	200	3-4	470 471				20030	609
ZΑ	20030	0447	1		λ	- 2	20041	1624		ZΑ	2003	3-4	471				20030	609
ZA	20030	0447	3		λ	- 2	2004(1624		Zλ	2003	3-4	473				20030	609
ZA	20030	0447	5		λ	- 7	20046	1624		Zλ	2003	3-4	475				20030	609
ZA	20030	0447	2		λ	- 1	20040	1625		ŽΑ	2003	3-4	472				20030	609
ZA	20030	0447	4		λ	- 7	20040	1625		ZΑ	2003	3-4	474				20030	609
NO	20030	0267	0		A	- 7	20030	0815		NO	2003	3-2	670				20030	612
NO	20030	0270	4		A	- 7	20030	2821		NO	2003	3-2	704			:	20030	613
	20042				A1	- 7	20041	1111		US.	2003	3-6	2480	10		:	20030 20030 20030 20030 20030 20030 20030	722
	20041				A1		20040			US	2003	3-6	9235	5		:	20031	023
	20041				Αl		20040			US	2003	3-7	9235 2237	4			20031	125
	20041				A1			708		US	2003	3-7	3642	6			20031	
	20041				A1 A2			1826		US	2004	6-7	2237 3642 7569 6692	9		- 2	20040	210
	200509				λZ	2	20050	414								- 2	20041	217
PRIORITY	APPLI	v. II	NFO.										5788		P	' '	20001	221
													8694		₽	,	20010	427
													3279	SP	P	' :	20000 20010	915
													5267	1		3 :	20010	914
													5560				20010	
													5793		λ	3 2	20011	219
										VS.	Z001	1-2	6966		A	1 2	20011	219
										NO.	2001	ı-U	5491	39	¥		20011	219
										AQ.	2001	1-0	5503	12	¥		20011	219
										AO.	2001	i - Ū	5511	20	¥	_ ?	20011 20011 20011 20011	219
										US	2001	1-3	4019		Ņ	3	20011	220
										US	2001	1-3	4683		A	1 2	20011	220
OTHER SC	NINCK (S	,,:			MARPA	¥ 1	3/:1	U923	4									

ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN 438204-95-69 (Continued)

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(protein kinase inhibitor; preparation of (pyrimidinylamino)pyrazoles as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease) 438204-95-6 HCAPLUS

2,4-Quinazolinediamine, N,N'-bis(5-ethyl-lH-pyrazol-3-yl)- (9CI) (CA

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

ANSWER 6 OF 9 BEAPLUS COPYRIGHT 2005 ACS on STN

(pyrazolylamino)quinazoline II was refluxed with thiophenol in t-BuOH to give III. In bioassays, I inhibited the following kinases with Ki values reported < 20 µH: GSK-3P (232 compds.), AURORA-2 (227 compds.), COK-2 (13 compds.), ERZ (8 compds.), AXT (10 compds.), and Human Src kinase (183 compds.). I are useful for the treatment of diseases associated with protein kinases, such as diabetes, cancer, and Alzheimer's disease (no data).

L4 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:555487 HCAPLUS
DOCUMENT NUMBER: 137:125169
TITLE: Preparation of 3-(4-pyrimidinylamino)-1H-pyrazoles as protein kinase inhibitors, especially of Aurora-2 and GSK-3

GSK-3 Bebbington, David: Charrier, Jean-Damien: Golec, Julian: Miller, Andrew: Knegtel, Ronald Vertex Pharmaceuticals Incorporated, USA PCT Int. Appl., 333 pp. CODEN: PIXED2 Patent INVENTOR (S): PATENT ASSIGNEE(S):

SOURCE

DOCUMENT TYPE: LANGUAGE: English
FAMILY ACC. NUM. COUNT: 14

US 6653301 US 2003105090

20030605

US 2001-26966

20011219

L4 ANS	VER	7 07	9	HCAP	ws	COP	YRIG	ET 2	005	ACS	on.	ST	N		Cont	ím	zed)	
ᄧ	1345	922			A1		2003	0924		EP	200	1-2	710	61			20011	219
	R:	AT,	BE,	Œ,	DE,	DX,	ES,	FR,	GB,	GF	L II	r.	LI,	w,	NL,	51	, MC,	PT,
		IE.	SI,	LT.	LV.	m.	RO,	MK.	CT.	A	. 71	R						
EP	1353	916			A2		2003	1022		EP	200	1-9	943	23			20011	219
	R:	AT.	BE.	Œ.	ĐK.	DX.	ES.	FR.	GB.	GF	. 17	r.	LI.	W.	NL.	SI	, HC,	PT.
					LV,								-	-	-			
EP	1355		,		A1	:	2003	1029		EP	2001	1-2	738	61			20011	219
			BE.	Œ.													, MC,	
	•				LV.									,		-	•	
BR	2001	1164	11				2003				2001		641	1			20011	219
NZ	5264	12			_													
JP	2004	1789	94		T2		20040	0617		JP	2002	2-5	579	38			20011	219
JÞ	2004	187	13		72		20041	0624		JP.	2002	2-5	659	76			20011	219
JÞ.	2004	194	79		72		20041	702		JP.	2002	-5	679	28			20011	219
115	2004	1481	14		11		20041	1028		115	2001	-2	200	5			20011	219
O.	1540	112	• •		À.		2004	1124		~	2001	-8	221				20011	210
W7	5264	,,,			î	. :	2005	1624		M7	2001	- 5	264	73			20011	219
115	2003	10414	54		T2 T2 T2 T2 A1 A		20030	3102		211	2001	3	169	~			20011 20011 20011 20011 20011 20011 20011	220
	6656		~		B2		20031	202		03	2007	3	•••	•			20011	220
	2003				Al		20030			ne	2001	- 3	4031				20011	220
	6727		,,		B2		20040			U.S	2001	3	.01	,			20011	220
	20030				λ		20040				2003						20030	600
	20030				λ		20040			40	2003		100					
	20030				Â		20040			*	2003		470					
	20030									**	2003		.70				20030 20030 20030 20030 20030 20030 20030 20030	600
	20030				A		20040 20040			٠.	2003		473				20030	600
	20030									ZA	2003		.73				20030	603
	20030				y		20040			ZA	2003		1/3				20030	609
					y		20040			ZA	2003						20030	609
	20030				λ		20040			24	2003	-4	1/4				20030	609
	20030				A		20030			MU.	2003)-Z	103				20030	613
					۸.		20030			WO	2003		/04				20030	613
	20042				A1		20041			US	2003	-6	2481	10			20030 20031	122
	20041				A1		20040			US	2003	-6	9Z3:	••			20031	023
	20041				Al Al		20040			US	2003	- //	223	74 26			20031	
	20041						20040										20031	
	20041		11		A1		20040				2004						20040	
	20050				A2	-	20050	1414						25	_		20041	
PRIORITY	APPI	м. 1	NPO.	. :										7P			20001	
										U5	2001	-21	694	19P	1	•	20010	427
										US	Z000)-Z.	3Z 75	15P	1		20000	915
										US	2001	-9:	Z6	"	- 1	13	20010	914
										US	Z001	-95	5560	"		IJ	20010 20000 20010 20010 20011 20011 20011 20011 20011 20011 20011	914
										JP	Z002	:-5	5793	58	,	IJ.	20011	Z19
										US	2001	-26	5966			11	20011	219
										MO	2001	-05	5491	139	•		20011	219
										wo	2001	-05	5494	101	•		20011	219
										WO.	Z001	-05	5503	112	•		Z0011	219
										US .	Z001	-34	1015	!		13	Z0011	Z20
										US	2001	-34	683	,	,	1	20011	220
OTHER SOL	URCE	5):			MARP	AT I	37:1	2516	9									

ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

ANSWER 7 OF 9 ECAPLUS COPYRIGHT 2005 ACS on STN (Continued)

The title compds. I [21 = N, CR8; 22 = N. CH; and at least one of 21 and 22 = N Rb, Rc = TR3, LZRB; CZRBRC = (un) substituted fused (betaro)cycle; Q = NR4, O, S, etc., RR1 = TD) D = (un) substituted anono- or bicyclic (betaro)aryl, betarocyclyl, carbocyclyl; T = a bond, alkylidene (un)interrupted by O, S, NR4, CO, etc.; Z = alkylidene; L = O, S, SO, SO2, etc.; R2, R2s = R, TWR6, or CZRZR2s = (un)substituted fused (betaro)aryl, betarocyclyl; Rs = R7, COR7, SOZR7, etc.; W = CO, COZ, CORR6, etc.; R6, R7 = H, alkyl or N(R6)2 or N(R7)2 = heterocyclyl, betaroaryl] were prepared for example, the (pyrazolylamino)quinazoline II was refluxed with thiophenol in tert-EvoRf to give III. In bioassays, I inhibited the following kinases with Ki values reported < 20 µH; GSK-39 (232 compds.), AURORA-2 (227 compds.), CDK-2 (13 compds.), ERK2 (8 compds.), AT (10 compds.), and Buman Src kinase (183 compds.), I are useful for the treatment of diseases associated with protein kinases, such as diabetes, cancer, and Altheimer's disease (no data).

43204-93-69.
Ri: PAC (Pharmacological activity), SPN (Synthetic preparation), TBU (Therapeutic use)) BIOL (Biological study); PREP (Preparation) USES (Uses)

(protein kinase inhibitor; preparation of (pyrinidinylamino)pyrazoles as protein kinase inhibitor; for treatment of cancer, diabetes, and Altheimer's disease)
43204-95-6 HCAPUS
2,4-Quinazolinediamine, N,N'-bis(5-ethyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)

LA ANSVER 8 OF 9
ACCESSION NUMBER:
DOCUMENT NUMBER:
137:57588
137:57588
137:57588
137:57588
Pyzazole compounds useful as protein kinase inhibitors, and therapeutic use thereof Golec, Julian; Pierard, Francoise; Charrier, Jann-Damien, Bebbington, Dawid Vertex Pharmaceuticals Incorporated, USA PCT Int. Appl., 87 pp.
COOMENT TYPE:
LANGUAGE:
FAMILY ACC. NUM. COUNT:
14
PATENT INFORMATION:
14 DOCUMENT TYPE: LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

						_						•						
	ENT				KIN	D -	DATE			APPL	ICAT	ION	NO.		D	ATB		
	2002				A2			0627								0011		
	2002				Ä3			0220			•••				•			
	V:			AL.				AZ,		BB.	BG.	BR.	BY.	BZ.	CA.	CH.	CN.	
								DM,										
								15,										
								MG,										
								SI,										
		US,	UZ,	VN,	YU,	ZA,	ZW											
	RW:	GH,	GM,	KB,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	UG,	ZH,	ZV,	AT,	BE,	CH,	
								GB,										
		BF,	ΒJ,	CF,	œ,	CI,	CM,	GA,	GN,	GQ,	G¥,	ML,	MR,	NE,	SN,	TD,	TG	
CA	2432	303			λA		2002	0829 0829		CA2	001-	2432	303		2	0011	219	
RO	2432 2002	0664	61															
	¥:	,	,	,				A2,										
								DM,										
								IS,										
								MG,										
								SI,	SK,	SL,	ŦJ,	TM,	TR,	17,	TZ,	Ųλ,	UG,	
					Yυ,													
	RV:							SD,										
								GB,										
			ВJ,	CF,		CI,	CH,	GΑ,	GN,	GQ,	GW,	ML,	MR,	NE,	SN,	TD,	TG	
	2432				AA.		2002	0906 0906		CA 2	001-	2432	223		21	0011	219	
MO	2002				Al		2002	0906		WO Z	001-	US50	31Z		- 20	011	219	
	¥:							λZ,										
								DM, IS,										
								MG,										
								SI,										
					YU,			51,	JA,	36,	10,	ın,	ıĸ,	11,	14,	un,	UG,	
	DU.							SD,		67	77	ne:	234	74	1.	94	~	
								GB.										
		-		_	~~	~~		GA,										
HS	2003	1041	51	٠.,	A1	٠.,		0102		US 2					20			
US	6653	300	•		R2						•••	-05.	•		-	~~		
US	2003	365	13		Al		2003	0220		US 2	001-	2516			20	011	219	
us	6664	247	-		B2		2003	1216					•					
US	2003	0550	58		Al		2003	0320		US 2	001-	2696	7		20	0112	219	
US	2003 6653 2003 6664 2003 2003 6653 2003 1345	782	75		Al		2003	1216 0320 0424 1125		US 2	001-	2700	i		20	00112		
US	6653	301	-		B2		2003	1125	•				-					
US	2003	10509	90		Al		2003	COOL		US 21	JU I ~	403 O			20	00112	219	
EP	13459	922			A1		2003	0924		EP 2	001-	2710	51		20	0112		
	R:	AT,	BE,	CH,	DB,	DX.	ES.	FR,	GB.	GR.	IT.	LI.	W,	NL.	SE.			
								MK,				-						
								-	-									

L4	ANSWER		9	BCAP		COE									Cont	im	ued)	
	EP 1355				A1			1029			2001							1219
	R:				DE,								J, 1	w,	NL,	51	E, MC	, PT,
			SI,	LT,	LV.	FI,								_				
	NZ 5264				A			0430			2001						2001	
	JP 2004				T2			0624			2002						2001	
	JP 2004				T2			0702			2002						2001	
	US 2004		14		Al			1028			2001						2001	
	CN 1549				A			1124			2001						2001	
	NZ 5264				A			0624			2001						2001	
	CA 2432				AA			0627			2001						2001	
	AU 2002				A5			0701			2002						2001	
	US 2003		64		A1			0102		US	2001	-34	683				2001	1220
	US 6656				B2			1202										
	US 2003		85		A1			0130		US	2001	-34	019				2001	1220
	US 6727				B2			0427										
	EP 1345				A2			0924			2001						2001	
	R:				DE,								I, I	w.	NL,	Sž	t, MC	, PT,
				LT,	LV,													
	JP 2004		92		72			0603			2002						2001	1220
	NZ 5264				λ			1028			2001			i			2001	
	ZA 2003				Α			0624			2003						2003	
	ZA 2003				λ			0624			2003						2003	
	ZA 2003				λ			0624			2003						2003	
	ZA 2003				λ			0624			2003						2003	
	ZA 2003				λ			0624			2003						2003	
	ZA 2003				λ			0624			2003						2003	
	ZA 2003				A			0625			2003						2003	
	ZA 2003				λ			0625			2003						2003	
	NO 2003				λ			0821			2003						2003	
	US 2004				A1			1111			2003						2003	
	US 2004				A1			0617			2003						2003	
	US 2004				Al			0812			2003						2003	
	US 2004				A1			0708			2003						2003	
	US 2004				A1			0826			2004						20040	
	JP 2005				A2		2005	0414			2004						2004	
PRIOR	UTY APP	LN. I	NPO.	. :							2000						20001	
											2001						20010	
											2000						20000	
											2001						20010	
											2001						20010	
											2002						20011	
											2001						2001	
											2001						20011	
											2001						20011	
											2001						20011	
											2001						20011	
										WO.	2001	-US4	1958	5		r	20011	220
OTHER	SOURCE	(5):			HARP	NT	137:	57586	,									

ANSWER R OF 9 REAPILIS COPYRIGHT 2005 ACS on STN

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE A39076-36-5 BCAPLUS
CN Acctandide, N-[4-[2-[(5-methyl-1H-pyrazol-3-yl)amino]-4-quinazolinyl]thio]phenyl]- (9CI) (CA INDEX NAME)

GI

CANE OR MORE TAUTCHERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 439076-37-6 HCAPLUS
CN 2-Quinazolinamine, 4-(6-benzothiszolylthio)-N-(5-methyl-1H-pyrazol-3-yl)(9C1) (CA INDEX NAME)

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 439076-38-7 HCAPLUS
CN Benzeneacetonttrile, 4-{[2-{(5-cyclopropyl-1H-pyrazol-3-yl)amino}-4quinazolinyl}oxy]- (9CI) | CA INDEX NAME)

ANSVER 8 OF 9 BICAPLUS COPYRIGHT 2005 ACS on STN

The invention describes pyrazole compds. I [Z1 = N, CR8; Q = O, 5, etc.; R1 = T-Ring D; T = valence bond, alkylidene chain; Ring D = 5-7-membered monocyclic ring, 8-10-membered bicyclic ring; R2, R2' = H, (un)substituted C1-6 aliphatic, (un)substituted C6-10 aryl, etc.; R8 = halo, NO2, CN, etc.]. The compds. are useful as protein kinase inhibitors, especially as inhibitors of Aurora-2 and GSK-3, for treating diseases such as cancer, diabetes, and Alishamer's disease.
439076-37-6 439076-38-7 439076-38-8
439076-37-6 439076-38-7 439076-38-8
439076-37-6 439076-41-2
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (pyrazole compds. as protein kinase inhibitors, and therapeutic use)
439076-30-9 HCAPLUS
2,4-Fyrinddinediamine, N4-1H-indazol-6-yl-N2-(5-methyl-1H-pyrazol-3-yl)-6-(phenylmethyl)- (9CI) (CA INDEX NAME)

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 439076-31-0 ECAPLUS
CN 2,4-Pyrindineediamine, 6-methyl-N2-(5-methyl-1H-pyrazol-3-yl)-N4-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)

ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE RN 439076-39-8 HCAPLUS
CN 2-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-4-{(3-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 439076-40-1 BCAPLUS
CN 2,4-Quinazolinediamine, N2-1H-indazol-3-yl-N4-(3-pyridinylmethyl)- (9CI)
(CA INDEX NAME)

OR MORE TAUTCHERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
439076-41-2 HCAPLUS
2-Quinazolinamine, N-1H-indazol-3-yl-4-(phenylmethoxy)- (9CI) (CA INDEX

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L4 ANSYER 9 OF 9 BCAPLUS COPTRIGHT 2005 ACS on STM
ACCESSION NUMBER: 2002:487556 BCAPLUS
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:47221
137:472 DOCUMENT TYPE: Patent English 14 LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

PATE	Off :	NO.			KIN	D	DATE			APPL	ICAT	ION	NO.		0	ATE	
															-		
WO 2							2002	0627		WO 2	001-	US 49	140		2	0011	219
WO 2	2002	0500	65		A3		2002	1024									
	V:	AS,	AG,	AL,	AM,	AT,	AU,	AZ,	BA,	BB,	BG,	BR,	BY,	BZ,	CA,	CH,	CN,
		œ,	CR,	αı,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	ES,	FI,	GB,	GD,	GE,	Œ,
		GΝ,	HR,	ÆU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KP,	KR,	KZ,	ĸ,	LK,	LR,
		LS,	LT,	w,	LV,	HA,	MD,	MG,	MK,	MN,	MV,	MX,	MZ,	MO,	NZ,	PH.	PL,
		PŤ,	RO,	RU,	SD,	SE,	SG,	SI,	SX,	SL,	TJ,	TH,	TR,	TT,	TZ,	UA,	UG,
		US,	UZ,	VN,	YU,	Zλ,	ZW										
	R¥:	GH,	GH,	KE,	LS,	MV,	HZ,	SD,	SL,	SZ,	TZ,	UG,	ZH,	ZV,	AT,	BE,	Œ,
		CY,	DE,	DK.	ES,	MI,	FR.	GB,	GR,	IE,	IT,	w,	MC,	NL,	PT,	SE,	TR,
		BF.	BJ,	CT.	œ,	CI,	CH,	GA,	GN,	GQ.	GW,	ML,	MR,	NE,	SN,	TD,	TG
CA 2	432	799			AA		2002	0627		CA 2	001-	2432	799		2	0011	219
AU 2	2002	340	47		A5		2002	0701		AU 2	002-	3404	7		2	0011	219
CA 2	432	303			λλ		2002	0829		CA 2	001-	2432	303		2	0011	219
WO 2	2002	0664	61		A1		2002	0829		WO 2	001-	US49	139		2	0011	219
	¥:	AΕ,	λG,	AL,	AM,	AT,	AU.	λZ,	BA,	BB,	BG,	BR,	BY,	BZ,	CA,	CE,	CN,
		œ,	CR,	α,	CZ,	DE,	DX,	DM,	DZ,	EC,	EE,	ES,	FI,	GB,	GD,	GE,	GH,
		GH,	HR.	HU,	ID,	IL,	IN,	IS,	JP,	KB,	KG,	KP,	KR,	KZ,	LC.	LK,	LR,
		LS,	LT,	w,	LV,	MA,	MD,	MG,	MK,	MN,	MV,	MX,	MZ,	NO,	NZ,	PH,	PL.
		PT,	RO,	RU,	SD,	SE,	SG,	SI,	SK,	SL,	TJ,	TM,	TR,	π,	TZ,	UA,	UG,
		US,	UZ,	VN,	ΥU,	Zλ,	ZV										
	RW:	GH,	GM,	KE,	LS,	MW,	MZ,	SD,	SL,	52,	TZ,	UG,	ZM,	ZV,	ΑŤ,	BK,	CH,
		CY,	DE,	DK,	ES,	FI,	FR,	GB,	GR,	IE,	IT,	w,	MC,	NL,	PT,	SE,	TR,
																TD,	
CA 2	432	223			λλ		2002	0906		CA 2	DO1-:	2432	223		21	0011	219
WO 2	002	0684	15		A1		2002	0906	1	WO 2	001-	US50:	312		21	0011	219
	v:															Œ,	
																GE,	
		GM,	HR,	HU,	ID,	IL,	IN,	15,	JP,	KE,	KG,	KP,	ĸR,	KZ,	LC,	LK,	LR,
		LS,	LT,	w,	LV,	Hλ,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NO,	NZ,	PH,	PL,
		PT.	RO,	RU,	SD,	SK,	SG,	SI,	SK,	SL,	IJ,	TM,	TR,	TT,	TZ,	UA,	UG,
		US,	UΖ,	VN,	YU,	Zλ,	Z¥										
	R¥:															BE,	
																SK,	
		BF,	ΒJ,	CF,	œ,	CI,	CH,	GA,	GN,	GQ,	G₩,	ML,	MR,	NE,	SN,	TD,	TG
US 2	0030	0041	51		A1		2003(0102	1	US 21	001-2	2697	5		20	3011	219
US 2003004161					B2		2003	1125									

ANSWER 9 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

(pyrazolylamino)quinazoline II was refluxed with thiophenol in t-BuOH to give III. In bioassays, I inhibited the following kinases with Xi values reported < 20 µH: GSK-38 (232 compds.), AMRORA-2 (227 compds.), CDX-2 (13 compds.), ERKZ (8 compds.), AKT (10 compds.), and Human Src kinase (183 compds.). I are useful for the treatment of diseases associated with protein kinases, such as diabetes, cancer, and Alzheimer's disease

14	LW	CVVO	9 08	•	ESC A D	LUS	m		HT 2	005	40	٠.		***			í		
-	He.	2001	10366			31	٠.	2007		003	110	200		251 <i>E</i>	. `	-	• • • •	2001: 2001: 2001: 2001: 2001:	
		2003	0.202	• 3		~.		2003	0220		us	200	71-	2310	•			2001	1219
	US	0004	26/			B2		2003	1216						_				
	US	2003	10550	68		Al		2003	0320		US	204	71-	2696	7			2001	1219
	บร	2003	10782	75		λl		2003	0424		US	208)1-	2700	1			2001	1219
- 1	US	6653	301			BZ		2003	1125										
	US	2003	1050	90		A1		2003	0605		US	200	11-	2696	6			2001	1219
	EP	1345	922			A1		2003	0924		RP.	201	11-	2710	61			2001	1219
		ъ.	AT	RE.	CH.	ng.	mr.	PS	-	GB	-G1			77	7,11	MT.	51	, MC	PT
						LV,								ш,	ш,	иш,	٠.		• • • •
	_	1245	925			-::		2002		C1,		•	· .					2001	210
	L.P					- ^2		2003	0924		EP.	200)1-	9850	59			2001	1219
		K:	AI,	BE,	Œ,	DE,	nk.	E5,	PH,	GB,	G)	K, 1	ŀΤ,	LI,	w,	NL,	51	, MC	PT,
			IE,	SI,	LT,	LV.	ZI,	RO,	ĸĸ,	CY,	N1	L, 1	r R						
1	EΡ	1355	905			A1		2003	1029		EP	200)1-:	2738	61			2001	1219
		R:	AΤ,	BE,	Œ,	DE,	DK,	ES,	FR,	GB,	G	a. 1	T.	LI.	w.	NL,	SE	, MC,	PT,
			IE.	SI.	LT.	LV,	FI.	RO.	MK.	CY.	AI	. 1	TR.						
1	NZ	5264	72	-		À		2004	0430		WZ.	20/	11-	5264	72			20011	219
	TP	2004	51620	91		72		2004	0603		TD	20/						20011	210
	70	2004	5107	44		+2		2004	0634		¥.	200	-	2212				20011	210
		2004	2101			12		2004	0024		JP	200	72-	2023	10			20011	217
3	32	2004	2134	/9		12		2004	0 102		JP	200)Z-:	5679	29			2001	219
	US	2004	2148	14		A1		2004	1028		US	200	11-	26997	2			2001	219
	CN.	1549	812			λ		2004	1124		CN	200)1-(12210	05			20011	219
1	ΝZ	5264	73			A		2005	0624		ΝZ	200	11-9	5264	73			20011	219
1	ΝZ	5264	69			A		2005	1029		NZ	200	1-9	52646	59			20011	219
ı	JS	2003	00416	54		A1		2003	0102		us	200	11-	3468	3			20011	220
t	15	6656	939			B2		2003	1202						•				
	15	2003	0228	15		11		2003	0130		116	200	11_1	4016				20011	220
ì	16	6727	251			92		2003	0437		03	200		,401	•			2001	220
:		2002	221			DZ.		2004	0421			200						20020	
	•••	2003	00446	30		•		2004	0624		24	200		408				20030	1003
3	~	2003	00446	59		A		2004	0624		ZA	200	3-4	1469				20030	609
2	ZA	2003	00447	70		λ		2004	0624		Zλ	200	13-4	470				20030	609
2	ZA	2003	00447	71		λ		2004	0624		Zλ	200	3-4	471				20030	1609
2	Z.A.	2003	00447	73		λ		2004	0624		Zλ	200	3-4	1473				20030	609
2	A.S	2003	00447	75		A		2004	0624		ZΑ	200	3-4	475				20030	609
2	A	2003	00447	12		λ		2004	0625		ZΑ	200	3-4	472				20030	609
2		2003	00447	14				2004	0625		72	200	3-4	474				20030	ena.
	20	2003	00267					2003	0818		WC	200	3_	671				20030	612
	<u>~</u>	2003	0027			;		2003	0010			200	3-6	704				20030	632
		2003	22101			Ω,		2003	1111			200	3-2	700				20030	722
	,,	2004	22979	•		^1		2004	1111		U.S	200	3-6	2460	,,,			20030	122
·	15	2004	11645	• 4		Αl		20040	0617	1	US	200	3-6	9235	.5			20031	023
t	JS	2004	15789	93		A1		20040	0812	1	US	200	3-7	2237	/4			20031	125
·	JS	2004	13278	11		A1		20040	0708		US	200	3-7	3642	26			20031	215
PRIORI	JS	2004	16714	1		A1		20040	0826	- 1	US	200	4-7	7569	9			20040	210
J	P	2005	09732	22		A2		20050	0414		JΡ	200	4-3	6692	!5			20041	217
PRIORI	TY	APP	LN. I	NPO.	:						US	200	0-2	5788	7P	F	•	20001	221
										i	US	200	1-2	8694	92	Ē	•	20010	427
										- 1	115	200	n-3	3270	5D			20000	016
											,,	200	1-0	5267	13.			20000	014
										. :		200		2201		- 1	2	20010	714
										•	73	200	1-3	3360			2	20010	914
											ı.P	200	2-5	5/93	, a	,	.3	20011	219
										,	JS	200	1-2	6966	,	A	.1	20011	219
										١	JO.	200	1-U	IS491	.39	¥	•	20011	219
										1	JO	200	1-U	15491	40	띹	1	20011	219
											10	200	1-U	5503	12	¥		20011	219
										ı	US.	200	1-3	4019	•	A	3	20011	220
										i	JS	200	1-3	4683		Ä	1	20011	220
OTHER	so	URCE	(S):			MARP	AT.	137:4	17221			_,_				•	_		
							•••												

ANSWER 9 OF 9 ECAPLUS COPYRIGHT 2005 ACS on STN (Continued)

ASSEMT 9 OF 9 HAPENS CUPRICHT ZUUS ACS ON STN (CONTINUED)
(no data).
48204-95-67, (5-Ethyl-1H-pyrazol-3-yl) [2-(5-ethyl-1H-pyrazol-3-yl)amino guinazolin-4-yl]amine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(Uses)
(protein kinase inhibitor; preparation of (pyrimidinylamino)pyrazoles as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)
438204-95-6 HCAPUS
2,4-Quinazolinediamine, N,N'-bis(5-ethyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE